Topline data were announced from a trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.
The trial of the once-daily drug—which mimics a gut hormone known as GLP-1 to control blood sugar and suppress ...
Study participants were randomly assigned to 1 of 3 treatment arms: lorundrostat 50mg once daily, lorundrostat 50mg daily with optional dose escalation to 100mg daily at week 6, or placebo.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback